Clarity Pharmaceuticals Ltd (ASX:CU6)
Australia · Delayed Price · Currency is AUD 3.600
+0.200 (5.88%)
At close: Mar 18, 2026
Clarity Pharmaceuticals Revenue
Clarity Pharmaceuticals had revenue of 5.81M AUD in the half year ending December 31, 2025, with 7.15% growth. This brings the company's revenue in the last twelve months to 10.58M, down -1.83% year-over-year. In the fiscal year ending June 30, 2025, Clarity Pharmaceuticals had annual revenue of 9.46M, down -17.76%.
Revenue (ttm)
10.58M
Revenue Growth
-1.83%
P/S Ratio
119.63
Revenue / Employee
120.23K
Employees
88
Market Cap
1.27B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 9.46M | -2.04M | -17.76% |
| Jun 30, 2024 | 11.51M | 1.71M | 17.41% |
| Jun 30, 2023 | 9.80M | 3.34M | 51.74% |
| Jun 30, 2022 | 6.46M | 3.26M | 102.06% |
| Jun 30, 2021 | 3.20M | 407.65K | 14.62% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Telix Pharmaceuticals | 1.21B |
| Mesoblast | 98.02M |
| Clinuvel Pharmaceuticals | 96.30M |
| Neuren Pharmaceuticals | 64.65M |
| PYC Therapeutics | 20.56M |
| Starpharma Holdings | 14.58M |
| Orthocell | 9.33M |
| Dimerix | 7.42M |